How many clinical trials are tracked for Systemic Lupus Erythematosus?

120 trials are tracked, 20 with published results.

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Log in / Sign up

Systemic Lupus Erythematosus

Subtypes of Systemic Lupus Erythematosus

Lupus Nephritis 26 Incomplete lupus erythematosus 1

107 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Systemic Lupus Erythematosus

120 trials tracked for Systemic Lupus Erythematosus: 29 in phase 3 or 4 and 20 with published results. The most-cited published study has 1834 citations.

120Trials tracked

29Phase 3 & 4

0Recruiting

20With published results

Phase distribution

Phase 4 8 Phase 3 21 Phase 2 62 Phase 1 9 Other / NA 20

Phase 4 Efficacy of Fish Oil in Lupus Patients Completed · 1,834 cited
Phase 3 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed · 235 cited
Phase 3 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed · 235 cited
Phase 3 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) Completed · 177 cited
Phase 3 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Completed · 111 cited
Phase 3 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Completed · 94 cited

Show 44 more trials

Phase 3 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed · 92 cited
Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 75 cited
Phase 4 Belimumab Assessment of Safety in SLE Completed · 49 cited
Phase 4 Acthar Gel for Active Systemic Lupus Erythematosus (SLE) Completed · 47 cited
Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 47 cited
Phase 3 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Completed · 43 cited
Phase 4 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease Completed · 41 cited
Phase 4 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Completed · 36 cited
Phase 3 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed · 36 cited
Phase 3 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Completed · 24 cited
Phase 4 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Completed · 15 cited
Phase 3 Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients Completed · 12 cited
Phase 3 A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus Completed · 7 cited
Phase 4 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed · 3 cited
Phase 4 Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) Completed
Phase 3 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed
Phase 3 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Completed
Phase 3 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Completed
Phase 3 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Completed
Phase 3 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed
Phase 3 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed
Phase 3 Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Completed
Phase 3 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed
Phase 2 A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus Completed
Phase 2 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Completed
Phase 2 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) Completed
Phase 2 A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) Completed
Phase 2 Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus Completed
Phase 2 A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus Completed
Phase 2 An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults Completed
Phase 2 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) Completed
Phase 2 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed
Phase 2 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) Completed
Phase 2 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus Completed
Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Completed
Phase 2 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Completed
Phase 2 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) Completed
Phase 2 Study of Anti-Malarials in Incomplete Lupus Erythematosus Completed
Phase 2 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed
Phase 2 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) Completed
Phase 2 Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus Completed
Phase 2 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed
Phase 2 JBT-101 in Systemic Lupus Erythematosus (SLE) Completed
Phase 2 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Completed

Showing the 50 most-cited and recently-updated of 120 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

‹ Prev 1 2 3 4 5 … 9 Next ›

Questions about Systemic Lupus Erythematosus

How do biologics compare to targeted drugs for treating systemic lupus erythematosus?

Biologics (e.g., anifrolumab, belimumab) and targeted drugs (e.g., telitacicept, upadacitinib) both treat SLE, but network meta-analyses show telitacicept may outperform belimumab for SRI-4 response, while anifrolumab and deucravacitinib work better for skin symptoms. Safety prof

Full answer →

How common is female sexual dysfunction in women with systemic lupus erythematosus according to recent studies?

Recent studies show that about 59% of women with systemic lupus erythematosus experience sexual dysfunction, which is significantly higher than in healthy women.

Full answer →